The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats

Fell, Matthew; Anjum, Nargis; Dickinson, Keith; Marshall, Kay; Peltola, L. M.; Vickers, Steven P.; Cheetham, Sharon C.; Neill, Joanna C.

doi:10.1007/s00213-007-0833-9

Cited by 55 publications

(47 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found unaltered prolactin levels following risperidone treatment, which is in contrast to other studies of daily, long-term risperidone treatment [40,43,57,58]. Because of the different routes of administration, comparing the administered doses between the present study and previous animal studies is difficult.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Risperidone Treatment Increases CB<sub>1</sub> Receptor Binding in Rat Brain

et al. 2009

View full text Add to dashboard Cite

Background/Aims: Body weight gain is a common side effect of treatment with antipsychotics, but the mechanisms underlying this weight gain are unknown. Several factors may be involved in antipsychotic-induced body weight gain including the cannabinoid receptor 1 (CB₁), the serotonin receptor 2C, the ghrelin receptor, neuropeptide Y, adiponectin and proopiomelanocortin. We investigated whether the expression of these factors was affected in rats chronically treated with the antipsychotic risperidone. Methods: Male Sprague-Dawley rats were treated with risperidone (1.0 mg/kg/day) or vehicle (20% hydroxypropyl β-cyclodextrin) for 28 days. Expression of the aforementioned factors were examined together with plasma prolactin and ghrelin levels. Results: No difference in body weight gained during treatment was observed between risperidone and vehicle treated rats, but plasma risperidone levels positively correlated with visceral fat mass. Risperidone treatment increased CB₁ receptor binding in the arcuate nucleus (40%), hippocampus (25–30%) and amygdala (35%) without concurrent alterations in the CB₁ receptor mRNA. Risperidone treatment increased adiponectin mRNA. Conclusion: The present study showed that risperidone treatment altered CB₁ receptor binding in the rat brain. Risperidone-induced adiposity and metabolic dysfunction in the clinic may be explained by increased CB₁ receptor density in brain regions involved in appetite and regulation of metabolic function.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…Risperidone treatment may cause sedation and has previously been associated with decreased locomotor activity in rats [42,43]. Therefore, we measured basal activity levels, which were measured for 24 h once per week for the last 3 weeks of the study.…”

Section: Resultsmentioning

confidence: 99%

Risperidone Treatment Increases CB<sub>1</sub> Receptor Binding in Rat Brain

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Consistent with previous studies, olanzapine caused significant metabolic dysregulation, 22,24,31,[37][38][39][40][41][42][43] evident as elevated fasting glucose levels, insulin resistance (greater HOMA-IR values) and glucose intolerance in the IGTT. To our knowledge, we assessed the effects of metformin, rosiglitazone and glyburide on these metabolic side effects in rats for the first time.…”

Section: Discussionsupporting

confidence: 90%

Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats

Boyda

Procyshyn²,

Tse

et al. 2012

J Psychiatry Neurosci

View full text Add to dashboard Cite

“…Also, previous studies have found cholesterol, triglycerides and LDL-cholesterol increase in olanzapine treated patients, and not in ziprasidone treated individuals 6,38 . Physical activity is significantly reduced in olanzapine treated patients 39,40 , but the OR of physical exercise in this study significantly favors olanzapine over ziprasidone treated patients and hence, does not explain the difference in weight gain.…”

Section: Discussioncontrasting

confidence: 65%

Ziprasidone versus Olanzapine in the weight gain associated with the treatment of schizophrenia: A six-month double-blind randomized parallel group study

et al. 2012

View full text Add to dashboard Cite

-Background and Objectives: Previous data from safety analysis indicate that olanzapine can result in substantial weight gain, while no change has been observed with ziprasidone. Obesity may be a threat to health and cause subjects to discontinue their antipsychotic medication. To further evaluate the differential effects of ziprasidone and olanzapine on weight gain, a study was carried out having body weight as the primary efficacy endpoint.Methods: A six-month randomized, double-blind, parallel study was carried out in male and female subjects aged 18-70 years with a primary diagnosis of schizophrenia (DSM-IV-TR) and a clinical condition requiring treatment initiation with a new antipsychotic, ziprasidone or olanzapine 1:1, to assess treatment-related weight changes. Fifty patients were included. Efficacy outcomes were assessed at baseline and at weeks 1, 4, 12, 18 and 24. The primary efficacy endpoint was the percent change from baseline in body weight at week 24. Safety was also assessed.Results: At week 24, there was a significantly greater increase in body weight (7.5%, p < 0.0001) in patients treated with olanzapine than in those treated with ziprasidone and EFFECTS OF ZIPRASIDONE VERSUS OLANZAPINE IN WEIGHT GAIN 249

show abstract

The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats

Cited by 55 publications

References 52 publications

Risperidone Treatment Increases CB<sub>1</sub> Receptor Binding in Rat Brain

Risperidone Treatment Increases CB<sub>1</sub> Receptor Binding in Rat Brain

Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats

Ziprasidone versus Olanzapine in the weight gain associated with the treatment of schizophrenia: A six-month double-blind randomized parallel group study

Contact Info

Product

Resources

About